Použití imunomodulace pro potenciaci chemoterapie polymerními cytostatiky
Cancer treatment with polymer-bound cytostatic drugs and its potentiation through immunomodulation
diploma thesis (DEFENDED)
View/ Open
Permanent link
http://hdl.handle.net/20.500.11956/24851Identifiers
Study Information System: 52521
Collections
- Kvalifikační práce [20084]
Author
Advisor
Referee
Drda Morávková, Alena
Faculty / Institute
Faculty of Science
Discipline
Genetics, Molecular Biology and Virology
Department
Department of Genetics and Microbiology
Date of defense
8. 6. 2009
Publisher
Univerzita Karlova, Přírodovědecká fakultaLanguage
Czech
Grade
Excellent
Cancer treatment with polymer-bound cytostatic drugs and its potentiation through immunomodulation Poly[N-2-(hydroxypropyl)-methacrylamide] (PHPMA) is a synthetic water soluble and biocompatible polymer which can be used as a carrier of a cytostatic drug and an antibody as a targeting moiety. The antibody ensures the site-specific delivery of the conjugate. Nevertheless, even polymeric conjugates without any tumor-specific targeting moiety are passively accumulated within solid tumors via so called Enhanced Permeability and Retention (EPR) effect, in case that their molecular wight is at least 40 kDa. Antibody-targeted polymeric drugs have been shown previously to have a cytostatic activity in vitro and an antitumor activity in vivo. Since treatment of cancer diseases in practice is far from such ideal conditions and many tumors have no strictly specific marker suitable for targeted therapy, upgrading of the treatment efficacy represents the major challenge. One of the possible ways how to improve insufficient chemotherapy outcome can be using of a combination of polymer-bound cytostatic drug and potent immunomodulation able to induce a robust anti-cancer immune response. In this study, we have used B cell leukemia BCL1 as an experimental tumor model. BCL1 cells express surface IgM with an unique...